Compare PNBK & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNBK | VYGR |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.4M | 222.4M |
| IPO Year | N/A | 2015 |
| Metric | PNBK | VYGR |
|---|---|---|
| Price | $1.57 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 167.9K | ★ 586.5K |
| Earning Date | 11-14-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $17,200,000.00 | ★ $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $2.65 |
| 52 Week High | $7.47 | $5.96 |
| Indicator | PNBK | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 49.57 |
| Support Level | $1.50 | $3.86 |
| Resistance Level | $1.66 | $4.22 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 32.00 | 65.44 |
Patriot National Bancorp Inc provides consumer and commercial banking services to individuals, small and medium-sized businesses, professionals, and municipalities in Fairfield and New Haven Counties in Connecticut and Westchester County, New York. Its products include checking accounts, savings accounts, money market accounts, time certificates of deposit, and individual retirement accounts. The Bank's lending portfolio is comprised of commercial mortgage and construction loans, commercial loans, home improvement loans, home equity lines of credit, and other personal loans. In addition, the Bank offers bank checks, money orders, automated teller machines, interactive teller machines, online and mobile banking, credit cards, and debit cards.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.